Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/095—Neisseria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]

Definitions

• TTP Thrombotic thrombocytopenic purpura
• aHUS atypical hemolytic uremic syndrome
• TTP chronic kidney disease
• aHUS can involve extrarenal manifestations, so it can be difficult to discern the two diseases solely by clinical presentation (see Cataland SR, Wu HM, Blood Rev., 2014;28(2):67-74).
• TTP is associated with a deficiency in
• ADAMTS 13 a plasma metalloprotease that cleaves von Willebrand factor (vWF) multimers, with the consequent appearance of ultralarge vWF (ULvWF) multimers in the blood circulation (see Tsai HM, Int. J. Hematol. 2010;91(1): 1-19).
• ADAMTS 13 deficiency in TTP is generally due to autoantibodies that typically are no longer detectable during remission. In 5% to 10% of cases, the enzymatic deficiency is congenital and caused by mutations in the ADAMTS 13 gene (see George JN, Blood. 2010;116(20):4060-4069).
• the mainstay of therapy in congenital TTP is fresh frozen plasma infusions or plasma exchange to supply enough ADAMTS 13 protein to cleave the ULvWF multimers (see George JN, Blood.
• prophylactic fresh frozen plasma is often administered every 2 to 3 weeks to maintain ADAMTS 13 levels high enough to cleave the ULvWF multimers and prevent the formation of microthrombi (see George JN, Blood. 2010; 116(20):4060-4069).
• plasma treatment is associated with morbidity and mortality, including the acute risk for allergic reactions/ anaphylaxis and transfusion-related acute lung injury and the long-term risk for infection (historically with hepatitis B virus, hepatitis C virus, and HIV and more recently with the prion-associated Creutzfeldt-Jacob disease, which is resistant to current inactivation procedures (see Scully M., Transfus Apher. Sci. 2014;51(1): 11-14). Accordingly, it is an object of the present invention to provide improved methods for treating patients (in particular, pediatric patients) with an ADAMSTS 13 deficiency and/or congenital TTP.
• compositions and methods for treating an ADAMSTS 13 deficiency in a human pediatric patient comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof.
• compositions and methods for treating congenital TTP in a human pediatric patient comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof.
• the anti-C5 antibody, or antigen binding fragment thereof is administered (or is for
• a particular clinical dosage regimen i.e., at a particular dose amount and according to a specific dosing schedule.
• An exemplary anti-C5 antibody is eculizumab comprising heavy and light chains having the sequences shown in SEQ ID NOs: 10 and 11, respectively, or antigen binding fragments and variants thereof.
• the antibody comprises the heavy and light chain CDRs or variable regions of eculizumab.
• the antibody comprises the CDRl, CDR2, and CDR3 domains of the VH region of eculizumab having the sequence set forth in SEQ ID NO: 7, and the CDRl, CDR2 and CDR3 domains of the VL region of eculizumab having the sequence set forth in SEQ ID NO: 8.
• the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.
• Another exemplary anti-C5 antibody is antibody BNJ441 (also known as ALXN1210) comprising the heavy and light chains having the sequences shown in SEQ ID NOs: 14 and 11, respectively, or antigen binding fragments and variants thereof.
• the antibody comprises the heavy and light chain complementarity determining regions (CDRs) or variable regions (VRs) of antibody BNJ441.
• the antibody comprises the CDRl, CDR2, and CDR3 domains of the heavy chain variable (VH) region of antibody BNJ441 having the sequence shown in SEQ ID NO: 12, and the CDRl, CDR2 and CDR3 domains of the light chain variable (VL) region of antibody BNJ441 having the sequence shown in SEQ ID NO:8.
• the antibody comprises CDRl, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18, and 3, respectively, and CDRl, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO:8, respectively.
• the antibody comprises a heavy chain constant region as set forth in SEQ ID NO: 13.
• the antibody comprises a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met-429-Leu and Asn-435-Ser substitutions at residues corresponding to methionine 428 and asparagine 434, each in EU numbering.
• FcRn human neonatal Fc receptor
• the antibody comprises CDRl, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 19, 18, and 3, respectively, and CDRl, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively and a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met-429-Leu and Asn-435-Ser substitutions at residues corresponding to methionine 428 and asparagine 434, each in EU numbering.
• FcRn human neonatal Fc receptor
• Another exemplary anti-C5 antibody is antibody BNJ421 comprising heavy and light chains having the sequences shown in SEQ ID NOs:20 and 11, respectively, or antigen binding fragments and variants thereof.
• the antibody comprises the heavy and light chain CDRs or variable regions of BNJ421.
• the antibody comprises the CDRl, CDR2, and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDRl, CDR2 and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO:8.
• the antibody comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO:8, respectively.
• the antibody competes for binding with, and/or binds to the same epitope on C5 as, the above-mentioned antibodies.
• the antibody has at least about 90% variable region amino acid sequence identity with the above- mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO: 12 and SEQ ID NO:8).
• methods of treating a human pediatric patient with an ADAMSTS 13 deficiency and/or congenital TTP comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof.
• the dose of the anti-C5 antibody, or antigen binding fragment thereof is a flat-fixed dose that is fixed irrespective of the weight of the patient.
• the anti-C5 antibody, or antigen binding fragment thereof may be administered at a fixed dose of 900 mg or 1,200 mg, without regard to the patient's weight.
• dosage regimens are adjusted to provide the optimum desired response (e.g., an effective response).
• the anti-C5 antibody, or antigen binding fragment thereof is administered (a) weekly at a dose of 900 mg for four weeks and (b) once every two weeks thereafter at a dose of 1,200 mg.
• the anti-C5 antibody, or antigen binding fragment thereof is administered for at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 40, 45, 50, 55, or 60 weeks. In another embodiment, the anti-C5 antibody, or antigen binding fragment thereof, is administered for at least one, two, three, four, five, or six years.
• the anti-C5 antibodies, or antigen binding fragments thereof, can be administered to a patient by any suitable means.
• the antibodies are formulated for intravenous administration.
• the patient can be administered one or more suitable therapeutic agents, prior to administration of the anti-C5 antibodies, or antigen binding fragments thereof.
• the patient is administered an antimeningococcal vaccine prior to treatment with the anti-C5 antibody, or antigen binding fragment thereof.
• the patient is administered one or more antibiotics prior to treatment with the anti-C5 antibody, or antigen binding fragment thereof.
• methods of treating a human pediatric patient with an ADAMSTS 13 deficiency comprising administering to the patient an effective amount of an anti-C5 antibody, or antigen binding fragment thereof.
• the ADAMTS 13 deficiency is associated with one or more ADAMTS 13 gene mutations.
• the ADAMTS 13 mutation is a guanine to adenine change at nucleotide 3,251 (which is predicted to cause a cysteine to tyrosine substitution at amino acid 1,084).
• the ADAMTS 13 mutation is a deletion of a cytosine at nucleotide 4,049 (resulting in a frameshift after the arginine at amino acid 1,351, which is predicted to lead to a premature stop codon 9 amino acids later.
• the ADAMTS 13 deficiency is associated with two ADAMTS 13 mutations, wherein the first ADAMTS 13 mutation is a guanine to adenine change at nucleotide 3,251 and the second ADAMTS 13 mutation is a deletion of a cytosine at nucleotide 4,049.
• the ADAMTS 13 deficiency is determined by undetectable levels of
• ADAMTS 13 activity as assessed by a collagen-binding assay and/or fluorescence resonance energy transfer (FRET) (e.g., using the ADAMTS 13 fluorogenic substrate FRETS-rVWF73).
• FRET fluorescence resonance energy transfer
• methods of treating a human pediatric patient with an ADAMTS 13 deficiency comprising intravenously administering eculizumab to the patient (a) weekly at a dose of 900 mg for four weeks and (b) once every two weeks thereafter at a dose of 1,200 mg, are provided.
• methods of treating a human pediatric patient with congenital TTP comprising intravenously administering eculizumab to the patient (a) weekly at a dose of 900 mg for four weeks and (b) once every two weeks thereafter at a dose of 1,200 mg, are provided.
• the patient Prior to treatment, with the anti-C5 antibodies, or antigen binding fragments thereof, the patient may exhibit one or more particular characteristics.
• the human pediatric patient has ultra large von Wildebrand factor (ULvWF) multimers circulating in the blood prior to treatment.
• the human pediatric patient has elevated levels of C3a in the plasma prior to treatment.
• the human pediatric patient has elevated levels of sC5b-9 in the plasma prior to treatment.
• the human pediatric patient has elevated levels of serum induced C5b-9 deposits on microvascular endothelial cells ex-vivo and C3 glomerular deposits in kidney biopsy specimens prior to treatment.
• the human pediatric patient has elevated levels of C5b-9 glomerular deposits in kidney biopsy specimens prior to treatment.
• the efficacy of the treatment methods provided herein can be assessed using any suitable means.
• Patients treated according to the methods disclosed herein preferably experience improvement in at least one sign of an ADAMTS 13 deficiency and/or congenital TTP.
• the treatment may produce at least one therapeutic effect selected from the group consisting of increased then normalized platelet count, normalized lactate dehydrogenase (LDH) levels, normalized serum creatinine levels, and normalized diuresis.
• the treatment results in a normalized platelet count, normalized lactate dehydrogenase (LDH) and normalized dieresis within 3 days.
• the treatment results in a normalized serum creatinine within 2 weeks.
• lactate dehydrogenase (LDH) levels can be used to evaluate
• patients treated according to the disclosed methods experience reductions in LDH levels by about 20%, 30%, 40%, 50%, 60%, 70%, 80% or more compared to no treatment.
• patients treated according to the disclosed methods experience reductions in LDH levels to near normal levels or to within 10%, or within 20% above what is considered the normal level.
• kits that include a pharmaceutical composition containing an anti-C5 antibody, or antigen binding fragment thereof, such as eculizumab, BNJ441, or BNJ421, and a pharmaceutically-acceptable carrier, in a therapeutically effective amount adapted for use in the methods described herein.
• the kit comprises:
• the kit comprises:
• FIG. 1 is a timeline depicting early clinical events and initiation of therapy.
• UTR refers to upper respiratory tract infection
• AKI refers to acute kidney injury.
• Figures 2A-2B are graphs depicting the Effect of eculizumab (Ecu) on platelet count ( Figure 2A) and serum-induced endothelial C5b-9 deposits in an ex vivo assay ( Figure 2B).
• Treatments shown in Figure 2A include hemodialysis (HD) and Ecu doses (arrows).
• Results shown in Figure 2B pertain to an ex vivo assay of serum-induced C5b-9 deposition on activated human microvascular endothelial cells.
• Figure 3 shows the rapid increase of platelet counts and restoration of diuresis in the patient following administration of the first dose of eculizumab (900 mg)
• Figure 4 depicts the recovery of kidney function after first eculizumab dose.
• Figure 5 depicts serum creatinine levels from day 0 to day 140.
• Figure 6 is a representation and localization of the two heterozygous ADAMTS 13 mutations found in the patient.
• Figure discloses SEQ ID NOS 21, 23, 22, 24, 21, 23, 21, and 23, respectively, in order of appearance.
• the term "subject” or “patient” is a human patient ⁇ e.g., a patient having an ADAMSTS 13 deficiency and/or congenital TTP).
• the term "pediatric patient” refers to an infant, child, or adolescent from birth up to the age of 18.
• the term "congenital” refers to a condition associated with genetic defect present at birth ⁇ e.g., whether inherited or caused by the environment).
• Thrombotic Thrombocytopenic Purpura also known as TTP or
• Moschcowitz syndrome is a rare disorder of the blood-coagulation system, which causes extensive microscopic clots to form in the small blood vessels throughout the body (see, e.g., Moake JL (2002), N. Engl. J. Med. 347 (8): 589-600). These small blood clots, called thrombi, can damage many organs including the kidneys, heart and brain. Most cases of TTP arise from severely reduced activity of the enzyme ADAMTS 13.
• ADAMTS 13 is a metalloprotease responsible for cleaving large multimers of von Willebrand factor (ULvWF) into smaller units.
• UvWF von Willebrand factor
• An ADAMTS 13 deficiency results in circulating ULvWF multimers , which increase platelet adhesion to areas of endothelial injury, particularly at arteriole-capillary junctions (see Tsai HM, Int. J. Hematol.
• ADAMTS 13 deficiency in TTP is generally due to autoantibodies that typically are no longer detectable during remission. In 5% to 10% of cases, the enzymatic deficiency is congenital and caused by mutations in the ADAMTS 13 gene (see George JN, Blood. 2010; 116(20):4060-4069).
• Effective treatment refers to treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder.
• a beneficial effect can take the form of an improvement over baseline, i.e., an improvement over a measurement or observation made prior to initiation of therapy according to the method.
• Effective treatment may refer to alleviation of at least one symptom of an ADAMSTS 13 deficiency and/or congenital TTP (e.g., peripheral thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and/or single or multiple organ failure of variable severity).
• an effective amount refers to an amount of an agent that provides the desired biological, therapeutic, and/or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and/or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
• an "effective amount” is the amount of anti-C5 antibody, or antigen binding fragment thereof, clinically proven to alleviate at least one symptom of an ADAMSTS 13 deficiency and/or congenital TTP.
• An effective amount can be administered in one or more administrations.
• the terms “fixed dose”, “flat dose” and “flat-fixed dose” are used interchangeably and refer to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient.
• the fixed or flat dose is therefore not provided as a mg/kg dose, but rather as an absolute amount of the agent (e.g., the anti-C5 antibody, or antigen binding fragment thereof,).
• antibody describes polypeptides comprising at least one antibody derived antigen binding site (e.g., VH/VL region or Fv, or CDR).
• Antibodies include known forms of antibodies.
• the antibody can be a human antibody, a humanized antibody, a bispecific antibody, or a chimeric antibody.
• the antibody also can be a Fab, Fab'2, ScFv, SMIP, Affibody®, nanobody, or a domain antibody.
• the antibody also can be of any of the following isotypes: IgGl , IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, and IgE.
• the antibody may be a naturally occurring antibody or may be an antibody that has been altered (e.g., by mutation, deletion, substitution, conjugation to a non-antibody moiety).
• an antibody may include one or more variant amino acids (compared to a naturally occurring antibody) which changes a property (e.g., a functional property) of the antibody.
• a property e.g., a functional property
• numerous such alterations are known in the art which affect, e.g., half-life, effector function, and/or immune responses to the antibody in a patient.
• the term antibody also includes artificial polypeptide constructs which comprise at least one antibody-derived antigen binding site.
• anti-C5 antibodies described herein bind to complement component C5 (e.g., human C5) and inhibit the cleavage of C5 into fragments C5a and C5b.
• complement component C5 e.g., human C5
• Anti-C5 antibodies (or VH/VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art. Alternatively, art recognized anti-C5 antibodies can be used. Antibodies that compete with any of these art-recognized antibodies for binding to C5 also can be used.
• An exemplary anti-C5 antibody is eculizumab comprising heavy and light chains having the sequences shown in SEQ ID NOs: 10 and 11, respectively, or antigen binding fragments and variants thereof.
• Eculizumab also known as Soliris ®
• Soliris ® is described in US Patent No: 6,355,245, the teachings or which are hereby incorporated by reference.
• Eculizumab is a humanized monoclonal antibody that is a terminal complement inhibitor.
• the antibody comprises the heavy and light chain CDRs or variable regions of eculizumab. Accordingly, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of eculizumab having the sequence set forth in SEQ ID NO: 7, and the CDR1, CDR2 and CDR3 domains of the VL region of eculizumab having the sequence set forth in SEQ ID NO: 8. In another embodiment, the antibody comprises heavy chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain CDR1, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.
• Another exemplary anti-C5 antibody is antibody BNJ441 comprising heavy and light chains having the sequences shown in SEQ ID NOs: 14 and 11, respectively, or antigen binding fragments and variants thereof.
• BNJ441 also known as ALXN1210
• ALXN1210 is described in PCT/US2015/019225 and US Patent No. 9,079,949, the teachings or which are hereby incorporated by reference.
• BNJ441 is a humanized monoclonal antibody that is structurally related to eculizumab (Soliris ® ).
• BNJ441 selectively binds to human complement protein C5, inhibiting its cleavage to C5a and C5b during complement activation. This inhibition prevents the release of the proinflammatory mediator C5a and the formation of the cytolytic pore-forming membrane attack complex C5b-9 while preserving the proximal or early components of complement activation (e.g., C3 and C3b) essential for the opsonization of microorganisms and clearance of immune complexes.
• complement activation e.g., C3 and C3b
• the antibody comprises the heavy and light chain CDRs or variable regions of BNJ441. Accordingly, in one embodiment, the antibody comprises the CDRl, CDR2, and CDR3 domains of the VH region of BNJ441 having the sequence set forth in SEQ ID NO: 12, and the CDRl, CDR2 and CDR3 domains of the VL region of BNJ441 having the sequence set forth in SEQ ID NO:8. In another embodiment, the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively. In another embodiment, the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO:8, respectively.
• Another exemplary anti-C5 antibody is antibody BNJ421 comprising heavy and light chains having the sequences shown in SEQ ID NOs:20 and 11, respectively, or antigen binding fragments and variants thereof.
• BNJ421 also known as ALXN121 1
• ALXN121 1 is described in PCT/US2015/019225 and US Patent No.9,079,949, the teachings or which are hereby incorporated by reference.
• the antibody comprises the heavy and light chain CDRs or variable regions of BNJ421. Accordingly, in one embodiment, the antibody comprises the CDRl, CDR2, and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDRl, CDR2 and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO:8. In another embodiment, the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively. In another embodiment, the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO:8, respectively.
• the positions of the CDRs or framework regions within a light or heavy chain variable domain can be as defined by Kabat et al. [(1991) "Sequences of Proteins of Immunological Interest.” NIH Publication No. 91-3242, U.S. Department of Health and Human Services, Bethesda, MD]. In such cases, the CDRs can be referred to as "Kabat CDRs” ⁇ e.g., "Kabat LCDR2" or "Kabat HCDR1"). In some embodiments, the positions of the CDRs of a light or heavy chain variable region can be as defined by Chothia et al.
• these regions can be referred to as “Chothia CDRs” ⁇ e.g., “Chothia LCDR2" or “Chothia HCDR3”).
• the positions of the CDRs of the light and heavy chain variable regions can be as defined by a Kabat- Chothia combined definition.
• these regions can be referred to as “combined Kabat-Chothia CDRs”. Thomas et al. [(1996) Mol Immunol 33(17/18): 1389- 1401] exemplifies the identification of CDR boundaries according to Kabat and Chothia definitions.
• an antibody binds to a protein antigen and/or the affinity for an antibody to a protein antigen are known in the art.
• the binding of an antibody to a protein antigen can be detected and/or quantified using a variety of techniques such as, but not limited to, Western blot, dot blot, surface plasmon resonance (SPR) method ⁇ e.g., BIAcore system; Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.), or enzyme-linked immunosorbent assay (ELISA).
• SPR surface plasmon resonance
• ELISA enzyme-linked immunosorbent assay
• the antibody competes for binding with, and/or binds to the same epitope on C5 as, the antibodies described herein.
• the term "binds to the same epitope" with reference to two or more antibodies means that the antibodies bind to the same segment of amino acid residues, as determined by a given method.
• Techniques for determining whether antibodies bind to the "same epitope on C5" with the antibodies described herein include, for example, epitope mapping methods, such as, x-ray analyses of crystals of antigen: antibody complexes which provides atomic resolution of the epitope and hydrogen/deuterium exchange mass spectrometry (HDX-MS).
• Antibodies that "compete with another antibody for binding to a target” refer to antibodies that inhibit (partially or completely) the binding of the other antibody to the target. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to a target, may be determined using known competition experiments. In certain embodiments, an antibody competes with, and inhibits binding of another antibody to a target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition may be different depending on which antibody is the "blocking antibody” (i.e., the cold antibody that is incubated first with the target). Competing antibodies bind to the same epitope, an overlapping epitope or to adjacent epitopes (e.g., as evidenced by steric hindrance).
• Anti-C5 antibodies, or antigen-binding fragments thereof described herein, used in the methods described herein can be generated using a variety of art-recognized techniques.
• Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see, Kohler & Milstein, Eur. J. Immunol. 6: 511- 519 (1976)). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host.
• compositions which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse, et ah, Science 246: 1275-1281 (1989).
• compositions comprising an anti-C5 antibody, or antigen binding fragment thereof.
• the composition comprises an antibody comprising the CDRl, CDR2, and CDR3 domains of the VH region of eculizumab having the sequence set forth in SEQ ID NO: 7, and the CDRl, CDR2 and CDR3 domains of the VL region of eculizumab having the sequence set forth in SEQ ID NO: 8.
• the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.
• the antibody comprises the heavy and light chain CDRs or variable regions of BNJ441.
• the antibody comprises the CDRl, CDR2, and CDR3 domains of the VH region of BNJ441 having the sequence set forth in SEQ ID NO: 12, and the CDRl, CDR2 and CDR3 domains of the VL region of BNJ441 having the sequence set forth in SEQ ID NO:8.
• the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO:8, respectively.
• the antibody comprises
• the antibody comprises the CDRl, CDR2, and CDR3 domains of the VH region of BNJ421 having the sequence set forth in SEQ ID NO: 12, and the CDRl, CDR2 and CDR3 domains of the VL region of BNJ421 having the sequence set forth in SEQ ID NO:8.
• the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs: 19, 18, and 3, respectively, and light chain CDRl, CDR2 and CDR3 domains having the sequences set forth in SEQ ID NOs:4, 5, and 6, respectively.
• the antibody comprises VH and VL regions having the amino acid sequences set forth in SEQ ID NO: 12 and SEQ ID NO:8, respectively.
• compositions can be formulated as a pharmaceutical solution, e.g., for administration to a subject for the treatment or prevention of a complement-associated disorder.
• the pharmaceutical compositions will generally include a pharmaceutically acceptable carrier.
• a pharmaceutically acceptable carrier refers to, and includes, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
• the compositions can include a pharmaceutically acceptable salt, e.g., an acid addition salt or a base addition salt, sugars, carbohydrates, polyols and/or tonicity modifiers.
• compositions can be formulated according to standard methods.
• Pharmaceutical formulation is a well-established art, and is further described in, e.g., Gennaro (2000) "Remington: The Science and Practice of Pharmacy," 20 th Edition, Lippincott, Williams & Wilkins (ISBN: 0683306472); Ansel et al. (1999) "Pharmaceutical Dosage Forms and Drug Delivery Systems," 7 th Edition, Lippincott Williams & Wilkins Publishers (ISBN:
• a composition can be formulated, for example, as a buffered solution at a suitable concentration and suitable for storage at 2-8°C (e.g., 4°C).
• a composition can be formulated for storage at a temperature below 0°C (e.g., -20°C or -80°C).
• the composition can be formulated for storage for up to 2 years (e.g., one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, 10 months, 11 months, 1 year, 11 ⁇ 2 years, or 2 years) at 2-8°C (e.g., 4°C).
• the compositions described herein are stable in storage for at least 1 year at 2-8°C (e.g., 4°C).
• compositions can be in a variety of forms. These forms include, e.g., liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
• liquid solutions e.g., injectable and infusible solutions
• dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
• the preferred form depends, in part, on the intended mode of administration and therapeutic application.
• compositions containing a composition intended for systemic or local delivery can be in the form of injectable or infusible solutions.
• compositions can be formulated for administration by a parenteral mode (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection).
• parenteral mode e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection.
• parenteral administration e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection.
• parenteral administration e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection.
• parenteral mode e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection.
• ADAMTS 13 deficiency in a human pediatric patient comprising administering to the patient an anti-C5 antibody.
• methods for treating congenital TTP in a human pediatric patient comprising
• Symptoms of congenital TTP include, but are not limited to, profound peripheral thrombocytopenia (e.g., a decrease in platelets) microangiopathic hemolytic anemia (MAHA, e.g., a subgroup of hemolytic anemia (loss of red blood cells through destruction) caused by mechanical factors in the small blood vessels) and single or multiple organ failure of variable severity.
• MAHA microangiopathic hemolytic anemia
• the human pediatric patient has ultra large von Willebrand factor (ULvWF) multimers circulating in the blood prior to treatment.
• UvWF von Willebrand factor
• the human pediatric patient has elevated levels of C3a in the plasma prior to treatment.
• the human pediatric patient has elevated levels of sC5b-9 in the plasma prior to treatment.
• the human pediatric patient has elevated levels of serum-induced C5b-9 deposits on microvascular endothelial cells ex vivo and C3 glomerular deposits in kidney biopsy specimens prior to treatment.
• the human pediatric patient has elevated levels of C5b-9 glomerular deposits in kidney biopsy specimens prior to treatment.
• the treatment may produce at least one therapeutic effect selected from the group consisting of a normalized platelet count, normalized lactate dehydrogenase (LDH) levels, normalized serum creatinine levels, and normalized dieresis.
• the treatment results in a normalized platelet count, normalized lactate dehydrogenase (LDH) and normalized dieresis within 3 days.
• the treatment results in a normalized serum creatinine within 2 weeks.
• the platelet count increases and then normalizes.
• lactate dehydrogenase (LDH) levels can be used to evaluate responsiveness to a therapy.
• LDH lactate dehydrogenase
• patients treated according to the disclosed methods experience reductions in LDH levels by about 20%, 30%, 40%, 50%, 60%, 70%, 80% or more compared to no treatment.
• patients treated according to the disclosed methods experience reductions in LDH levels to near normal levels or to within 10%, or within 20% above what is considered the normal level.
• kits which include a pharmaceutical composition containing an anti-C5 antibody, or antigen binding fragment thereof, such as eculizumab, and a
• kits optionally also can include instructions, e.g., comprising administration schedules, to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition contained therein to administer the composition to a patient having an
• the kit also can include a syringe.
• kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the anti-C5 antibody, or antigen binding fragment thereof, for a single administration in accordance with the methods provided above.
• Instruments or devices necessary for administering the pharmaceutical composition(s) also may be included in the kits.
• a kit may provide one or more pre-filled syringes containing an amount of the anti-C5 antibody, or antigen binding fragment thereof.
• the present invention provides a kit for treating an ADAMTS 13 deficiency in a human pediatric patient, the kit comprising:
• the present invention provides a kit for treating an ADAMTS 13 deficiency in a human pediatric patient, the kit comprising:
• the present invention provides a kit for treating congenital TTP in a human pediatric patient, the kit comprising:
• the present invention provides a kit for treating congenital TTP in a human pediatric patient, the kit comprising:
• ADAMTS 13 test results were available (antimeningococcal vaccination and antibiotic prophylaxis were administered before eculizumab initiation). The response was excellent ( Figures 2-5) and within 3 days, the platelet count, lactate dehydrogenase level, and diuresis normalized. Accordingly, dialysis therapy was discontinued. Serum creatinine levels decreased to 1.78 mg/dL (eGFR, 36 mL/min/1.73 ml) and the severity of the patient's anemia lessened (hemoglobin, 8.9 g/dL).
• thrombocytopenia platelet count of 11 3103/mL, with diffuse petechial lesions
• microangiopathic hemolysis with normal kidney function (eGFR, 115 mL/min/1.73 ml).
• ex vivo testing of the patient's serum showed elevated C5b-9 deposits on microvascular endothelial cells.
• eculizumab (1,200 mg) was reintroduced, promptly resolving the thrombocytopenia within 24 hours and the petechial lesions disappeared within 48 hours ( Figure 2).
• the results shown in Figure 2B pertain to an ex vivo assay of serum-induced C5b-9 deposition on activated human microvascular endothelial cells.
• serum diluted 1:2 with test medium
• pre-Ecu pre-Ecu
• post- Ecu post- Ecu
• Fluorescent staining on the endothelial cell surface was calculated by analyzing 15 fields.
• the first mutation is a guanine to adenine change at nucleotide 3,251 of the complementary DNA, which is predicted to cause a cysteine to tyrosine substitution at amino acid 1,084, and has been previously reported in patients with TTP (see, e.g., Loirat C, et al., Curr. Opin. Pediatr. 2013;25(2):216-224; Lotta LA, et al, Blood. 2012;120(2):440-448; and Hing ZA, et al., Br. J. Haematol.
• the second mutation is a previously unpublished frameshift [from deletion of the cytosine at nucleotide 4,049 of the complementary DNA] after the arginine at amino acid 1,351, which is predicted to lead to a premature stop codon 9 amino acids later (see Figure 6). Taken together, screening results were consistent with a diagnosis of congenital TTP.
• vWF multimers favor the degradation of the C3 activation product C3b by CFI
• ULvWF multimers which are present in the circulation of patients with TTP, do not (Feng S, et al., Blood. 2015; 125(6): 1034- 1037), which further supports the hypothesis that ADAMTS 13 plays a role in modulating the alternative complement pathway.
• ADAMTS 13 deficiency could conceivably have caused excessive assembly and impaired the degradation of complement components on the ULvWF multimers anchored to the microvascular endothelium, as well as complement-mediatedinjury, mimicking the events associated with genetic complement dysregulation of aHUS. Chapin et al.
• DIQMTQS PS S LS AS VGDR VTITC GAS ENIYG ALNW YQQKPGKAPKLLIYG A TNLADGVPSRFS GS GS GTDFTLTIS S LQPEDFAT YYCQNVLNTPLTFGQGTK
• DIQMTQS PS S LS AS VGDR VTITC GAS ENIYG ALNW YQQKPGKAPKLLIYG ATNLADG VPS RFS GS GS GTDFTLTIS S LQPEDFAT Y YC QN VLNTPLTFGQ GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Endocrinology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (3)

Applications Claiming Priority (4)

Publications (1)

Family

ID=57200050

Family Applications (1)

Country Status (4)

Cited By (3)

Families Citing this family (1)

Citations (2)

• 2016
  • 2016-09-23 WO PCT/IB2016/001419 patent/WO2017055908A1/en not_active Ceased
  • 2016-09-23 EP EP16785560.0A patent/EP3356402A1/en not_active Withdrawn
  • 2016-09-23 US US15/762,207 patent/US20180237509A1/en not_active Abandoned
  • 2016-09-23 JP JP2018515541A patent/JP2018528975A/ja active Pending

Patent Citations (2)

Non-Patent Citations (40)

Also Published As

Similar Documents

Legal Events